Luminex Corporation was incorporated in May 1995 and began commercial production of the first generation system in 1997. Luminex® (NASDAQ: LMNX) develops, manufactures and markets innovative biological testing technologies with applications throughout the life science and diagnostic industries. The Company’s open-architecture xMAP® Technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately. Systems using xMAP Technology perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. Using lasers and high-speed digital-signal processors, the analyzer simultaneously identifies the bioassay and measures the results, all in real time.
Luminex Vision Statement: Breakthrough solutions to improve health and advance science.

Type
Public
HQ
Austin, US
Size (employees)
914 (est)+15%
Luminex is headquartered in Austin, US

Luminex Office Locations

Luminex has offices in Austin, Madison, 's-Hertogenbosch, Toronto and in 2 other locations
Austin, US
Shanghai, CN
Minato-ku, JP
Toronto, CA
's-Hertogenbosch, NL
Madison, US

Luminex Metrics

Luminex Summary

Market capitalization

$737.5 m

Closing share price

$18.1
Luminex's current market capitalization is $737.5 m.

Luminex Financials

Luminex's revenue is $10.7 m in FY, 2013
FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$10.7 m$227 m$237.7 m$270.6 m

Revenue growth, %

2021.3%4.7%13.9%

Gross profit

$143.6 m$159.9 m$168.7 m

Operating expense total

$138.9 m$131.7 m$131.4 m

EBIT

$4.8 m$28.1 m$37.4 m

Income tax expense

$6.1 m$9.5 m$10.4 m

Net Income

$7.1 m$39 m$36.9 m$13.8 m

Operating cash flow

$25.1 m$23.8 m$36.9 m

Luminex Market Value History

Luminex Online Presence

Luminex Company Life

You may also be interested in